AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology
Healthcare
$5.22 +0.82%
+$0.04 today
- Market cap
- $198.07M
- Beta
- -0.98
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.01
52W Low $1.00High $6.91
Volume 0.79M
Average 0.29M
Balance Sheet
Inspect the capital base behind the business.
Assets
$61.95M
FY 2025 · Annual
-32.7% YoYLiabilities
$8.89M
FY 2025 · Annual
-13.2% YoYEquity
$53.06M
FY 2025 · Annual
-35.2% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12.1M | 27.22M | 15.65M | 21.35M | 19.94M |
| Short-term Investments | 46.46M | 68.84M | 91.65M | 62.27M | 38.06M |
| Net Receivables | 0 | 0 | 1.4M | 300K | 900K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.55M | 2.56M | 3.21M | 2.34M | 1.04M |
| Total Current Assets | 60.11M | 98.62M | 110.51M | 86.26M | 59.94M |
| Property, Plant & Equipment (Net) | 0 | 53K | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 3.49M | 3.22M | 27.19M | 5.02M | 2.01M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.72M | 667K | 1.04M | 804K | 0 |
| Total Non-current Assets | 5.21M | 3.94M | 28.24M | 5.83M | 2.01M |
| Total Assets | 65.32M | 102.56M | 138.74M | 92.09M | 61.95M |
| Account Payables | 1.06M | 2.12M | 2.68M | 3.32M | 3.02M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 330K | 6K | 4.69M | 2.47M | 3.28M |
| Total Current Liabilities | 3.4M | 7.19M | 14.04M | 10.24M | 8.72M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 13K | 2K | 0 | 0 | 170K |
| Total Non-current Liabilities | 13K | 2K | 0 | 0 | 170K |
| Total Liabilities | 3.41M | 7.19M | 14.04M | 10.24M | 8.89M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (47.38M) | (89.72M) | (154.46M) | (205.78M) | (240.95M) |
| Accumulated OCI | (27K) | (374K) | 275K | 31K | 57K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 61.91M | 95.37M | 124.7M | 81.85M | 53.06M |
| Total Debt | 0 | 53K | 0 | 0 | 0 |
| Net Debt | (12.1M) | (27.17M) | (15.65M) | (21.35M) | (19.94M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $53.5M |
| Short-term Investments | $31.8M |
| Receivables | $300.0K |
| Other Current | $1.9M |
| Total Current Assets | $87.5M |
| Total Assets | $87.5M |
Analysis
Selected assets total $87.5M for Latest. The largest visible component is Cash & Equivalents at $53.5M, about 61.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 6, 2026 |
How much cash does ANTX have?
AN2 Therapeutics, Inc. (ANTX) reported $19.94M in cash and equivalents in fiscal 2025.
How much debt does ANTX carry?
AN2 Therapeutics, Inc. (ANTX) reported $0.00 of total debt, with net debt of -$19.94M.
Continue the stock analysis
Jump to another research area for this company.